Small molecule · Inhibitor of PARP1 and PARP2 · developed by Impact Therapeutics
Senaparib is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase (PARP) 1 and 2. It selectively binds to PARP1 and PARP2, preventing PARP-mediated DNA repair of single-strand breaks via the base-excision repair pathway, leading to accumulation of DNA strand breaks, genomic instability, and apoptosis. It is being studied in ovarian cancer, fallopian tube cancer, primary peritoneal cavity cancer, small cell lung cancer, and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06617923 | Phase 2 | Ovary Cancer | Recruiting | IBO |
| NCT04434482 | Phase 1/2 | Advanced Solid Tumours | Completed | IBO |
| NCT04089189 | Phase 2 | Ovarian Cancer | Completed | IBO |
| NCT07019194 | Phase 1 | Solid Tumor | Completed | IBO |
| NCT05391048 | Phase 1 | Solid Tumor | Completed | IBO |
| NCT07030439 | Phase 1 | Solid Tumor | Completed | IBO |
| NCT04584515 | Phase 1 | Solid Tumor | Completed | IBO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fallopian Tube CancerOvary CancerPrimary Peritoneal Cavity CancerAdvanced Solid TumoursOvarian CancerSmall Cell Lung CancerSolid Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the IBO page.
See IBO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBO catalysts and pipeline →